ATRC  Atricure Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Medical/Dental Instruments

Market Cap.

194.2M

Vuru Grade

23.50/100

Current Price

$9.28
-0.02 (-0.22%)

Growth Price

$0.13
Overvalued by 98.55%

Stability Price

$0.20
Overvalued by 97.89%

Company Metrics

  • 0 P/E
  • 2.70 P/S
  • 5.04 P/B
  • -0.46 EPS
  • -34.52% Cash ROIC
  • 1.31 Cash Ratio
  • 0.00 / N/A % Dividend
  • 103,039.00 Avg. Vol.
  • 15.67M Shares
  • 194.2M Market Cap.

Company Description

AtriCure, Inc., a medical device company, develops, manufactures, and sells cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac tissue. Its primary product line includes Isolator Synergy Bipolar Radio-Frequency Ablation Clamps for open-heart procedures and minimally invasive procedures; ablation and sensing unit, a compact power generator that delivers bipola...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

ATRICURE INC. : AtriCure Reports First Quarter 2013 Financial Results
4-traders (press release) - May 2, 2013
AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in the development of technologies and solutions for the treatment of atrial fibrillation, or Afib, and systems for the exclusion of the left atrial appendage, today announced ...
AtriCure (ATRC) Releases Quarterly Earnings Results, Misses Estimates By ... - Daily Political
AtriCure Rating Increased to Hold at TheStreet (ATRC)
The Utah People's Post - 2 hours ago
AtriCure, Inc. is a medical device company. The Company is developing, manufacturing and selling cardiac surgical ablation systems designed to create lesions, or scars, in cardiac, or heart, tissue.
CE Mark for Abbott's Xience Xpedition 48 - Analyst Blog
NASDAQ - May 22, 2013
... developed markets in 2013 coupled with weak economic conditionsand a mixed global economy. Abbott Labs currently carries a Zacks Rank #3 (Hold).
Here's why Chemed stock bounced back after Medicare suit
Business Courier of Cincinnati (blog) - May 20, 2013
What little bad news there was for local companies last week was confined mainly to smaller stocks. AtriCure Inc. (Nasdaq: ATRC) lost 5 percent while Ceco Environmental Corp.
BIOLASE Inc (BIOL) Shareholders: Have You Seen This Crucial Data?
Insider Monkey (blog) - Apr 29, 2013
BIOLASE Inc (NASDAQ:BIOL) In the 21st century investor's toolkit, there are dozens of methods investors can use to monitor their holdings.
Health-Care Stocks That Made Healthy Gains
Barron's - May 21, 2013
Please include your daytime telephone number and credentials. The opinions contained in Investors' Soapbox in no way represent those of Barrons.
Top Gainers in After-hours Today, May 6
MarketsNTrade - May 6, 2013
AtriCure Inc. (NASDAQ:ATRC) is currently trading at $8.82 up 2.3% in after-hours on 3330 shares traded. ATRC is trading 5.77% above its 50 day moving average and 14.00% above its 200 day moving average.
CE Mark for STJs ILUMIEN OPTIS
Zacks.com - May 17, 2013
Medical devices major, St. Jude Medical Inc. ( STJ - Analyst Report ) has won CE Mark approval for its ILUMIEN OPTIS Percutaneous Coronary Intervention (PCI) Optimization System.
DIARY-NON S&P WEEK AHEAD
Reuters - May 2, 2013
... 0.07 2 0.09 02 May AMC Q1 2013 athenahealth, Inc. 0.23 15 0.17 02 May BMO Q4 2013 ATK 1.98 10 1.86 02 May AMC Q1 2013 AtriCure, Inc. -0.11 6 -0.10 02 May BMO Q1 2013 Attunity Ltd. N/A N/A N/A 02 May AMC Q1 2013 American Vanguard 0.46 ...
CE Mark for STJs Ellipse amp; Assura
Zacks.com - May 13, 2013
St. Jude Medical Inc. ( STJ - Analyst Report ) has won CE Mark approval for its Ellipse and SJM Assura portfolio of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds).